MAM
CGEM icon

Martingale Asset Management’s Cullinan Oncology CGEM Stock Holding History

Martingale Asset Management’s Portfolio CGEM Stock Details CGEM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-20,932
Closed -$158K – 770
2025
Q2 		$158K Sell
20,932
-1,200
-5% -$9.64K ﹤0.01% 766
2025
Q1 		$168K Sell
22,132
-16,413
-43% -$157K ﹤0.01% 746
2024
Q4 		$469K Buy
38,545
+5,703
+17% +$82K 0.01% 617
2024
Q3 		$550K Buy
32,842
+18,820
+134% +$334K 0.01% 610
2024
Q2 		$245K Sell
14,022
-28,507
-67% -$607K 0.01% 726
2024
Q1 		$725K Hold
42,529
– – 0.01% 539
2023
Q4 		$433K Hold
42,529
– – 0.01% 637
2023
Q3 		$385K Hold
42,529
– – 0.01% 648
2023
Q2 		$458K Hold
42,529
– – 0.01% 631
2023
Q1 		$435K Buy
42,529
+900
+2% +$9.92K 0.01% 645
2022
Q4 		$439K Buy
41,629
+10,613
+34% +$129K 0.01% 639
2022
Q3 		$398K Buy
+31,016
New +$418K 0.01% 662

Other funds holding CGEM

MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Martingale Asset Management's CGEM Position: Q3 2025 in Review

Martingale Asset Management sold out of Cullinan Oncology (CGEM) in Q3 2025, closing a stake of 20,932 shares — an estimated $158K sold.

Martingale Asset Management first reported a position in CGEM in Q3 2022 and held it in 12 quarters. The position peaked at $725K in Q1 2024. 145 funds tracked by Wall St. Rank hold CGEM as of Q3 2025.

  • Martingale Asset Management reported no remaining Cullinan Oncology position as of Q3 2025 after selling out during the quarter.
  • Martingale Asset Management sold 20,932 Cullinan Oncology shares in Q3 2025, an estimated $158K.
  • Martingale Asset Management first reported a position in Cullinan Oncology in Q3 2022 and held it in 12 quarters.
  • Martingale Asset Management's Cullinan Oncology position peaked at $725K in Q1 2024.
  • 145 funds tracked by Wall St. Rank held Cullinan Oncology as of Q3 2025.

Based on Martingale Asset Management's 13F filing for Q3 2025, filed 13 Nov 2025.